HighTower Advisors
DTIL icon

HighTower Advisors’s Precision BioSciences DTIL Stock Holding History

HighTower Advisors’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,483
Closed -$53K – 3485
2022
Q4 		$53K Sell
1,483
-597
-29% -$23.6K ﹤0.01% 3023
2022
Q3 		$81K Buy
2,080
+783
+60% +$37.2K ﹤0.01% 2809
2022
Q2 		$63K Buy
1,297
+790
+156% +$46.4K ﹤0.01% 2876
2022
Q1 		$47K Buy
+507
New +$68.9K ﹤0.01% 3077
2021
Q4 		– Sell
-1,375
Closed -$476K – 3341
2021
Q3 		$476K Buy
+1,375
New +$466K ﹤0.01% 2081
2020
Q4 		– Sell
-613
Closed -$113K – 2670
2020
Q3 		$113K Buy
613
+223
+57% +$44.4K ﹤0.01% 2212
2020
Q2 		$97K Buy
+390
New +$85.4K ﹤0.01% 2124

Other funds holding DTIL

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighTower Advisors's DTIL Position: Q1 2023 in Review

HighTower Advisors sold out of Precision BioSciences (DTIL) in Q1 2023, closing a stake of 1,483 shares — an estimated $53K sold.

HighTower Advisors first reported a position in DTIL in Q2 2020 and held it in 7 quarters. The position peaked at $476K in Q3 2021. 86 funds tracked by Wall St. Rank hold DTIL as of Q1 2023.

  • HighTower Advisors reported no remaining Precision BioSciences position as of Q1 2023 after selling out during the quarter.
  • HighTower Advisors sold 1,483 Precision BioSciences shares in Q1 2023, an estimated $53K.
  • HighTower Advisors first reported a position in Precision BioSciences in Q2 2020 and held it in 7 quarters.
  • HighTower Advisors's Precision BioSciences position peaked at $476K in Q3 2021.
  • 86 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2023.

Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.